Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Summary

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

Timeline

Start

2026-06

Primary completion

2029-12

Completion

2030-01

Outcome

Outcome not reported

Stopped (Enrollment): “A business decision to place screening/enrollment on hold. Study redesign/amendment pending additional Ampligen-related data from an ongoing Phase I-II open label study (NCT05927142)”

Publications

• Background El Haddaoui H, Brood R, Latifi D, Oostvogels AA, Klaver Y, Moskie M, Mustafa DA, Debets R, van Eijck CHJ. Rintatolimod (Ampligen(R)) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program. Cancers (Basel). 2022 Mar 8;14(6):1377. doi: 10.3390/cancers14061377.

Drugs

Indications